Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of Pyrilutamide (KX-826) Topical Solution in Chinese Adult Men With Androgenetic Alopecia
CTR20213036Phase 3Completed
- Sponsor
- Suzhou Kaixi Pharmaceutical
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in androgenetic alopecia (AGA) comparing Pyrilutamide topical solution with Placebo topical solution (2 arms). Primary endpoint: Change from baseline in target area non-vellus hair count (TAHC) at 24 weeks. Started Nov 2021; status: completed.
02
Drugs
pyrilutamide
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on CTR20213036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213036.